Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ injections deliver nicotinamide adenine dinucleotide directly to support mitochondrial function and cellular ATP production. NAD+ levels naturally decline with age, declining approximately 50% by midlife, which may impact energy metabolism and stress resilience.

For individuals considering NAD+ therapy, understanding your baseline metabolic biomarkers and genetic predispositions can help support a more informed conversation with your healthcare provider. PlexusDx focuses on precision-wellness frameworks that incorporate genetic and biomarker insights into treatment planning.

How NAD+ Supports Cellular Energy and Why Baseline Status Matters

NAD+ functions as a coenzyme in more than 500 enzymatic reactions, primarily in energy production pathways (glycolysis, citric acid cycle, oxidative phosphorylation) and stress-response regulation. Injectable NAD+ aims to replenish systemic levels to support ATP synthesis and mitochondrial resilience in tissues with high energy demand.

Baseline NAD+ status varies by individual age, metabolic health, and lifestyle factors. Some individuals naturally maintain higher NAD+ levels, while others may benefit from supplementation. Biomarker assessment including NAD+/NADH ratio, lactate clearance, and mitochondrial markers can help contextualize treatment need alongside clinical evaluation.

NAD+ Injection Dosing, Administration Formats, and Treatment Protocols

NAD+ injections are available in intravenous (IV), intramuscular (IM), and subcutaneous formats. Dosing typically ranges from 250 mg to 1000 mg per administration, with protocols varying from acute loading phases to maintenance schedules. IV delivery provides rapid systemic availability, while IM and subcutaneous routes offer convenience with potentially slower absorption kinetics.

Administration Route Typical Dosing Range Onset Timeline Clinical Considerations
Intravenous (IV) 500–1000 mg per infusion Minutes to hours Rapid systemic delivery; requires clinical setting; frequent dosing protocols (1–3 times weekly)
Intramuscular (IM) 250–500 mg per injection Hours to days Slower absorption than IV; office-based or home administration; weekly dosing typical
Subcutaneous 250–500 mg per injection Hours to days Similar timeline to IM; self-administered option; emerging clinical data
Oral/Precursors (NMN, NR) 250–1000 mg daily Hours; variable bioavailability Convenience; limited systemic NAD+ elevation; intestinal metabolism reduces direct availability

Metabolic Biomarkers That Can Inform NAD+ Treatment Decisions

Before initiating NAD+ therapy, baseline assessment of NAD+/NADH ratio, mitochondrial respiratory capacity, lactate clearance, and circulating NAD+ levels can provide clinical context. These biomarkers may help identify whether NAD+ depletion is a limiting factor in the individual's metabolic picture or whether other pathways (mitochondrial function, antioxidant capacity) require concurrent attention.

Genetic variants in NAD+ metabolism (NAMPT, SIRT genes, CD38) and energy-production pathways may predict individual variation in NAD+ synthesis and response to supplementation. Consulting with a healthcare provider who reviews both biomarker and genetic context can help tailor dosing and monitor efficacy more precisely.

Safety Profile, Adverse Effects, and Provider Consultation Framework

NAD+ injections are generally well-tolerated. Reported side effects include injection-site reactions, transient flushing, mild nausea, and headache. Systemic adverse events are uncommon at therapeutic doses. However, NAD+ may influence sirtuin activity and cellular autophagy, requiring individual assessment, especially in patients with cancer history, immune-system conditions, or metabolic disorders.

NAD+ therapy is not appropriate for all individuals. Providers should evaluate contraindications (certain malignancies, immune dysregulation), drug interactions, and whether treatment aligns with clinical goals. Regular monitoring of energy levels, subjective biomarkers (mood, stamina), and objective biomarkers (NAD+, lactate, mitochondrial function) helps assess benefit and guides protocol adjustments.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for metabolic efficiency and energy-pathway responsiveness, though NAD+ supplementation is distinct from GLP-1 peptide therapies. Genetic variants in mitochondrial function, sirtuins, and NAD+ biosynthesis (NAMPT, SIRT1/3/6) are available through comprehensive metabolic genetic assessments and should be interpreted with a qualified healthcare provider.

While PlexusDx specializes in compounded GLP-1 therapies (semaglutide, tirzepatide, and dual-compound protocols), individuals exploring NAD+ therapy can benefit from understanding their broader metabolic and genetic landscape. Genetic predispositions in energy-metabolism pathways may inform whether NAD+ supplementation aligns with personalized wellness goals, but genetics do not predict exact NAD+ response.

A comprehensive conversation with your healthcare provider should integrate baseline biomarker status, genetic context, and clinical goals. For those exploring multiple precision-wellness tools—including NAD+ therapy and GLP-1-based metabolic support—understanding your genetic and biomarker profile can support more coordinated, informed treatment planning.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the primary mechanism by which NAD+ injections work?

NAD+ serves as a coenzyme in energy-production pathways and stress-response systems. Injectable NAD+ aims to replenish systemic levels, supporting ATP synthesis, mitochondrial function, and cellular resilience. Effects depend on baseline NAD+ status and individual metabolic context.

How often should NAD+ injections be administered, and what dosing schedule is typical?

Dosing varies by protocol and route. IV protocols commonly use 500–1000 mg once to three times weekly; IM/subcutaneous typically ranges 250–500 mg weekly. Treatment duration and frequency should be determined by a qualified healthcare provider based on goals and response.

Are there biomarkers I should check before starting NAD+ therapy?

Baseline assessment of NAD+/NADH ratio, mitochondrial function markers, lactate clearance, and circulating NAD+ levels may provide clinical context. A healthcare provider can determine which biomarkers are relevant to your individual situation and treatment goals.

What are the most common side effects of NAD+ injections?

Common effects include injection-site reactions, transient flushing, mild nausea, and headache. Serious adverse events are uncommon at therapeutic doses. Individuals with certain medical conditions or medications should discuss safety with their provider before treatment.

Can genetic testing predict how well I will respond to NAD+ therapy?

Genetic variants in NAD+ biosynthesis and mitochondrial pathways may provide context for metabolic efficiency, but genetics alone do not predict exact NAD+ response. A provider should interpret genetic and biomarker findings together with your clinical history and treatment goals.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves